

Certification of Health Care Provider for  
Employee's Serious Health Condition  
(Family and Medical Leave Act)

U.S. Department of Labor

Wage and Hour Division



DO NOT SEND COMPLETED FORM TO THE DEPARTMENT OF LABOR; RETURN TO THE PATIENT

OMB Control Number: 1235-0003

Expires: 5/31/2018

**SECTION I: For Completion by the EMPLOYER**

**INSTRUCTIONS to the EMPLOYER:** The Family and Medical Leave Act (FMLA) provides that an employer may require an employee seeking FMLA protections because of a need for leave due to a serious health condition to submit a medical certification issued by the employee's health care provider. Please complete Section I before giving this form to your employee. Your response is voluntary. While you are not required to use this form, you may not ask the employee to provide more information than allowed under the FMLA regulations, 29 C.F.R. §§ 825.306-825.308. Employers must generally maintain records and documents relating to medical certifications, recertifications, or medical histories of employees created for FMLA purposes as confidential medical records in separate files/records from the usual personnel files and in accordance with 29 C.F.R. § 1630.14(c)(1), if the Americans with Disabilities Act applies, and in accordance with 29 C.F.R. § 1635.9, if the Genetic Information Nondiscrimination Act applies.

Employer name and contact: \_\_\_\_\_

Employee's job title: \_\_\_\_\_ Regular work schedule: \_\_\_\_\_

Employee's essential job functions: \_\_\_\_\_

Check if job description is attached: \_\_\_\_\_

**SECTION II: For Completion by the EMPLOYEE**

**INSTRUCTIONS to the EMPLOYEE:** Please complete Section II before giving this form to your medical provider. The FMLA permits an employer to require that you submit a timely, complete, and sufficient medical certification to support a request for FMLA leave due to your own serious health condition. If requested by your employer, your response is required to obtain or retain the benefit of FMLA protections. 29 U.S.C. §§ 2613, 2614(c)(3). Failure to provide a complete and sufficient medical certification may result in a denial of your FMLA request. 20 C.F.R. § 825.313. Your employer must give you at least 15 calendar days to return this form. 29 C.F.R. § 825.305(b).

Your name: \_\_\_\_\_  
First Middle Last

**SECTION III: For Completion by the HEALTH CARE PROVIDER**

**INSTRUCTIONS to the HEALTH CARE PROVIDER:** Your patient has requested leave under the FMLA. Answer, fully and completely, all applicable parts. Several questions seek a response as to the frequency or duration of a condition, treatment, etc. Your answer should be your best estimate based upon your medical knowledge, experience, and examination of the patient. Be as specific as you can; terms such as "lifetime," "unknown," or "indeterminate" may not be sufficient to determine FMLA coverage. Limit your responses to the condition for which the employee is seeking leave. Do not provide information about genetic tests, as defined in 29 C.F.R. § 1635.3(f), genetic services, as defined in 29 C.F.R. § 1635.3(e), or the manifestation of disease or disorder in the employee's family members, 29 C.F.R. § 1635.3(b). Please be sure to sign the form on the last page.

Provider's name and business address: \_\_\_\_\_

Type of practice / Medical specialty: \_\_\_\_\_

Telephone: (\_\_\_\_\_) \_\_\_\_\_ Fax: (\_\_\_\_\_) \_\_\_\_\_

**PART A: MEDICAL FACTS**

1. Approximate date condition commenced: \_\_\_\_\_

Probable duration of condition: \_\_\_\_\_

**Mark below as applicable:**

Was the patient admitted for an overnight stay in a hospital, hospice, or residential medical care facility?

\_\_\_ No \_\_\_ Yes. If so, dates of admission:

\_\_\_\_\_

Date(s) you treated the patient for condition:

\_\_\_\_\_

Will the patient need to have treatment visits at least twice per year due to the condition? \_\_\_ No \_\_\_ Yes.

Was medication, other than over-the-counter medication, prescribed? \_\_\_ No \_\_\_ Yes.

Was the patient referred to other health care provider(s) for evaluation or treatment (e.g., physical therapist)?

\_\_\_ No \_\_\_ Yes. If so, state the nature of such treatments and expected duration of treatment:

\_\_\_\_\_

2. Is the medical condition pregnancy? \_\_\_ No \_\_\_ Yes. If so, expected delivery date: \_\_\_\_\_

3. Use the information provided by the employer in Section I to answer this question. If the employer fails to provide a list of the employee's essential functions or a job description, answer these questions based upon the employee's own description of his/her job functions.

Is the employee unable to perform any of his/her job functions due to the condition: \_\_\_ No \_\_\_ Yes.

If so, identify the job functions the employee is unable to perform:

\_\_\_\_\_

4. Describe other relevant medical facts, if any, related to the condition for which the employee seeks leave (such medical facts may include symptoms, diagnosis, or any regimen of continuing treatment such as the use of specialized equipment):

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

**PART B: AMOUNT OF LEAVE NEEDED**

5. Will the employee be incapacitated for a single continuous period of time due to his/her medical condition, including any time for treatment and recovery? \_\_\_ No \_\_\_ Yes.

If so, estimate the beginning and ending dates for the period of incapacity: \_\_\_\_\_

6. Will the employee need to attend follow-up treatment appointments or work part-time or on a reduced schedule because of the employee's medical condition? \_\_\_ No \_\_\_ Yes.

If so, are the treatments or the reduced number of hours of work medically necessary?  
\_\_\_ No \_\_\_ Yes.

Estimate treatment schedule, if any, including the dates of any scheduled appointments and the time required for each appointment, including any recovery period:

\_\_\_\_\_

Estimate the part-time or reduced work schedule the employee needs, if any:

\_\_\_\_\_ hour(s) per day; \_\_\_\_\_ days per week from \_\_\_\_\_ through \_\_\_\_\_

7. Will the condition cause episodic flare-ups periodically preventing the employee from performing his/her job functions? \_\_\_ No \_\_\_ Yes.

Is it medically necessary for the employee to be absent from work during the flare-ups?  
\_\_\_ No \_\_\_ Yes. If so, explain:

\_\_\_\_\_

\_\_\_\_\_

Based upon the patient's medical history and your knowledge of the medical condition, estimate the frequency of flare-ups and the duration of related incapacity that the patient may have over the next 6 months (e.g., 1 episode every 3 months lasting 1-2 days):

Frequency : \_\_\_\_\_ times per \_\_\_\_\_ week(s) \_\_\_\_\_ month(s)

Duration: \_\_\_\_\_ hours or \_\_\_\_\_ day(s) per episode

**ADDITIONAL INFORMATION: IDENTIFY QUESTION NUMBER WITH YOUR ADDITIONAL ANSWER.**

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_  
**Signature of Health Care Provider** **Date**

If submitted, it is mandatory for employers to retain a copy of this disclosure in their records for three years. 29 U.S.C. § 2616; 29 C.F.R. § 825.500. Persons are not required to respond to this collection of information unless it displays a currently valid OMB control number. The Department of Labor estimates that it will take an average of 20 minutes for respondents to complete this collection of information, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. If you have any comments regarding this burden estimate or any other aspect of this collection information, including suggestions for reducing this burden, send them to the Administrator, Wage and Hour Division, U.S. Department of Labor, Room S-3502, 200 Constitution Ave., NW, Washington, DC 20210. **DO NOT SEND COMPLETED FORM TO THE DEPARTMENT OF LABOR; RETURN TO THE PATIENT.**

**Important: Please note only data that has clinical mapping will be shared/transmitted.**

This health record is for date range : 01/01/2018 to 01/01/2019

Please note that below sections represents the most current data on record and are not specific to the date range: Demographics, Smoking Status, Problems, Medications, Allergies, Immunizations, Health Concerns, and UDI.

## Patient Details

| Patient name  | Contact info                                  | Patient IDs                    | Sex  |
|---------------|---|--------------------------------|------|
| Max Meindl    | 5 E AUSTIN ST<br>BELLVILLE, TX 77418-2201, US | <b>149178</b><br><b>149178</b> | Male |
| June 21, 1951 | tel:832-293-3671                              |                                |      |

## LANGUAGE

English

## RACE

## ETHNICITY

**Performer** FERNANDO COLATO

**Contact Info** 2700 E 29th Street  
BRYAN, TX 778022586  
Tel: 979-774-4008

**Performer** Provider Migration

**Contact Info**

## PROBLEMS

| Type    | Condition   | ICD9-CM Code | ICD10-CM Code | Onset Dates | Condition Status | SNOMED Code    |
|---------|---|--------------|---------------|-------------|------------------|----------------|
| Problem | Morbid (severe) obesity due to excess calories                |              | E66.01        |             | Active           | 83911000119104 |
| Problem | Abnormal cardiovascular function study                        |              | R94.30        |             | Active           | 274525000      |
| Problem | Arteriosclerosis of native coronary artery w/ angina pectoris |              | I25.119       |             | Active           | 194828000      |
| Problem | Body mass index (BMI) of 40.0-44.9 in adult                   |              | Z68.41        |             | Active           | 408512008      |
|         |   |              |               |             |                  |                |

|         |       |  |       |  |        |          |
|---------|-------|--|-------|--|--------|----------|
| Problem | Edema |  | R60.9 |  | Active | 79654002 |
|---------|-------|--|-------|--|--------|----------|

## ALLERGIES

| Allergen (clinical drug ingredient) | Drug/Non Drug Allergy documented on EMR | Reaction | Allergy Type     | Onset Date | Status |
|-------------------------------------|---|----------|------------------|------------|--------|
|                                     | IODINE AND IODIDE CONTAINING PRODUCTS   | Rash     | Non Drug Allergy |            | Active |
| Lisinopril                          | LISINOPRIL(NDC Code:00143-9713-01)      | Cough    | Drug Allergy     |            | Active |

## ENCOUNTERS From 2018-01-01 To 2019-01-01

| Encounter                       | Location   | Date               | Provider           | Diagnosis  |
|---------------------------------|--|--------------------|--------------------|--|
| CENTRAL TEXAS HEART CENTER PLLC | 2700 E 29th Street<br>Ste 220, 235 & 330<br>BRYAN, TX<br>778022586 | 26<br>Dec,<br>2018 | FERNANDO COLATO    | Arteriosclerosis of native coronary artery w/ angina pectoris I25.119 ;<br>Abnormal cardiovascular function study R94.30 ; Morbid (severe) obesity due to excess calories E66.01 and<br>Body mass index (BMI) of 40.0-44.9 in adult Z68.41 |
| CENTRAL TEXAS HEART CENTER PLLC | 2700 E 29th Street<br>Ste 220, 235 & 330<br>BRYAN, TX<br>778022586 | 26<br>Dec,<br>2018 | FERNANDO COLATO    | Arteriosclerosis of native coronary artery w/ angina pectoris I25.119  |
| CENTRAL TEXAS HEART CENTER PLLC | 2700 E 29th Street<br>Ste 220, 235 & 330<br>BRYAN, TX<br>778022586 | 17<br>Dec,<br>2018 | FERNANDO COLATO    | Arteriosclerosis of native coronary artery w/ angina pectoris I25.119  |
| CENTRAL TEXAS HEART CENTER PLLC | 2700 E 29th Street<br>Ste 220, 235 & 330<br>BRYAN, TX<br>778022586 | 09<br>Dec,<br>2018 | Provider Migration |  |
| CENTRAL TEXAS HEART CENTER PLLC | 2700 E 29th Street<br>Ste 220, 235 & 330<br>BRYAN, TX<br>778022586 | 08<br>Dec,<br>2018 | Provider Migration |  |
|                                 | 235 W Palm St  | 31                 |                    |  |

|                   |                            |              |                    |
|-------------------|----------------------------|--------------|--------------------|
| BELLVILLE<br>CTHC | BELLVILLE, TX<br>774181372 | Oct,<br>2018 | FERNANDO<br>COLATO |
|-------------------|----------------------------|--------------|--------------------|

## IMMUNIZATIONS

No Information

## SOCIAL HISTORY

Tobacco Use:

| Social History Observation       | Description    | Date |
|----------------------------------|----------------|------|
| Details (start date - stop date) | Current Smoker |      |

Sex Assigned At Birth:

| Social History Observation | Description |
|----------------------------|-------------|
| Sex Assigned At Birth      | Unknown     |

Tobacco Use/Smoking

| Question  | Answer         | Notes |
|-----------|----------------|-------|
| Are you a | current smoker |       |

## REASON FOR REFERRAL From 2018-01-01 To 2019-01-01 16:11:10

|                               |   |
|-------------------------------|---|
| Reason                        | PET   |
| AuthType                      | PET   |
| Diagnosis                     | Arteriosclerosis of native coronary artery w/ angina pectoris |
| Referral Organization         | CENTRAL TEXAS HEART CENTER PLLC                               |
| Referring Provider First Name | FERNANDO  |
| Referring Provider Last Name  | COLATO  |
| Referring Provider Specialty  | Cardiology  |
| Referring Provider Phone      | 979-774-4008  |
| Referring Provider email      | fcolato@centraltexasheart.com                                 |
| Referred Organization         | CENTRAL TEXAS HEART CENTER PLLC                               |
| Referred Provider             | COLATO, FERNANDO JOSE   |
|                               |   |

|                                    |  |
|------------------------------------|--|
| <b>Referred Address</b>            | 2700 E 29th Street,Ste 220, 235 & 330,BRYAN,TX,778022586 |
| <b>Referred Provider Specialty</b> | Cardiology   |

## VITAL SIGNS From 2018-01-01 To 2019-01-01

|                                 |                         |              |
|---------------------------------|-------------------------|--------------|
| <b>Heart Rate</b>               | 88 /min                 | 26 Dec, 2018 |
| <b>Heart Rate</b>               | 76 /min                 | 31 Oct, 2018 |
| <b>Weight</b>                   | 329.8 lbs               | 26 Dec, 2018 |
| <b>Weight</b>                   | 330.80 lbs              | 31 Oct, 2018 |
| <b>Height</b>                   | 5'10" in                | 26 Dec, 2018 |
| <b>Height</b>                   | 70.00 in                | 31 Oct, 2018 |
| <b>BMI</b>                      | 47.32 kg/m2             | 26 Dec, 2018 |
| <b>BMI</b>                      | 47.46 kg/m2             | 31 Oct, 2018 |
| <b>Respiratory Rate</b>         | 0 /min                  | 31 Oct, 2018 |
| <b>Oximetry</b>                 | 0 %                     | 31 Oct, 2018 |
| <b>Temperature</b>              | 0.00 degrees Fahrenheit | 31 Oct, 2018 |
| <b>Head Circumference</b>       | 0.00 in                 | 31 Oct, 2018 |
| <b>Blood pressure systolic</b>  | 130 mm Hg               | 26 Dec, 2018 |
| <b>Blood pressure diastolic</b> | 60 mm Hg                | 26 Dec, 2018 |

## MEDICATIONS

| <b>Medication</b>                      | <b>SIG (Take, Route, Frequency, Duration)</b>        | <b>Start Date</b> | <b>End Date</b> | <b>Status</b> |
|--|--|-------------------|-----------------|---------------|
| Potassium Chloride ER 10 MEQ           | take 1 tablet by oral route every day with food ORAL |                   |                 | Active        |
| Furosemide 20 MG                       | take 1 tablet by oral route 2 times every day ORAL   |                   |                 | Active        |
| hydrochlorothiazide 25 mg tablet 25 MG | take 1 tablet by oral route every day ORAL           |                   |                 | Active        |
| Losartan Potassium 100 MG              | take 1 tablet by oral route every day ORAL           |                   |                 | Active        |
|  |  |                   |                 |               |



|                                    |   |  |  |        |
|------------------------------------|---|--|--|--------|
| PredniSONE 50 MG                   | 1 tablet Orally twice a day for 4 days                    |  |  | Active |
| Isosorbide Mononitrate ER 60 MG    | take 1 tablet by oral route every day in the morning ORAL |  |  | Active |
| Metoprolol Succinate ER 50 MG      | take 1 tablet by oral route every day ORAL                |  |  | Active |
| Omega-3 350 mg-235 mg-90 mg-597 mg | ORAL  |  |  | Active |
| atorvastatin 80 mg tablet 80 MG    | take 1 tablet by oral route every day ORAL                |  |  | Active |
| Clopidogrel Bisulfate 75 MG        | take 1 tablet by oral route every day ORAL                |  |  | Active |
| Aspirin 81 MG                      | take 150 mg tablet by oral route every day ORAL           |  |  | Active |

## PROCEDURES

No Information

## RESULTS

No Results

## REASON FOR VISIT

No Information

## Goals Section

No Information

## Health Concerns

No Information

## MEDICAL EQUIPMENT

No Information

## MENTAL STATUS

No Information

## FUNCTIONAL STATUS

No Information

## ASSESSMENTS

| Encounter Date | Diagnosis  |
|----------------|--|
| 26 Dec, 2018   | Body mass index (BMI) of 40.0-44.9 in adult (ICD-10 - Z68.41)                    |
| 26 Dec, 2018   | Arteriosclerosis of native coronary artery w/ angina pectoris (ICD-10 - I25.119) |
| 17 Dec, 2018   | Arteriosclerosis of native coronary artery w/ angina pectoris (ICD-10 - I25.119) |
| 26 Dec, 2018   | Arteriosclerosis of native coronary artery w/ angina pectoris (ICD-10 - I25.119) |
| 26 Dec, 2018   | Abnormal cardiovascular function study (ICD-10 - R94.30)                         |
| 26 Dec, 2018   | Morbid (severe) obesity due to excess calories (ICD-10 - E66.01)                 |

## PLAN OF TREATMENT

### Medication

| Medication Name  | Sig                                    | Start Date | Stop Date |
|------------------|--|------------|-----------|
| PredniSONE 50 MG | 1 tablet Orally twice a day for 4 days |            |           |

### Treatment Notes

| Assessment  | Notes  |
|---|--|
| Arteriosclerosis of native coronary artery w/ angina pectoris | Stress test with apical moderate ischemia. He has an old LAD and RCA stents. Will further risk stratify with a LHC. We spoke about LHC. Risks include but not limited to: death, stroke, MI, need for emergency surgery, need for transfusion, groin hematoma, retroperitoneal bleed, anemia, infection. All questions were answered. Patient agrees to proceed with the above procedure. We spoke about possible PCI. Risks include but not limited to: Stroke, death, vessel dissection, perforation, need for emergency surgery, failed intervention, need for repeat procedure, restenosis & acute stent thrombosis. All questions were answered. Pt agrees to proceed w/ procedure. DES if needed. Right radial access. |
| Abnormal  |  |

cardiovascular  
function study

Apical ischemia.

## Referrals

Referral  
Date

Details

PET, FERNANDO COLATO, 2700 E 29th Street, BRYAN, TX, 778022586,  
979-774-4008

## Care Team

Guardian

Max Meindl

Contact  
info

5 E AUSTIN ST  
BELLVILLE, TX 77418-2201, US  
Tel: 832-293-3671

©*Powered by eClinicalWorks*